Collaborative initiatives and novel AI tools are helping to advance lung cancer screening, but participation barriers and disparities persist despite guideline expansions.
Key Details
- 1Lung cancer screening uptake with low-dose CT (LDCT) increased from 4.5% in 2023 to 16% in 2024, with state variation from 9.7% to 35.5%.
- 2AI deep-learning tools (e.g., from Radboud) have reduced false-positive nodule results by nearly 40%.
- 3Barriers to high screening rates include insurance preauthorization, patient knowledge, provider communication, and logistical factors.
- 4The ACR Lung Cancer Screening Registry (LCSR) is evolving into the Early Lung Cancer Detection Registry (ELCDR) to improve tracking and follow-up of both screening and incidental nodules.
- 5Guideline updates expanded eligibility, but disparities in demographic participation remain and nodule overdiagnosis is a concern.
- 6RSNA 2025 and other conferences will feature major sessions on personalized AI risk tools and screening strategies.
Why It Matters
This update summarizes substantial increases in lung cancer screening rates, highlights ongoing logistical challenges, and details the integration of AI to improve accuracy and efficiency in screening. These trends directly impact clinical workflows, patient outcomes, and the evolving role of radiologists in multidisciplinary care.
Source
AuntMinnie
Related News
•HealthExec
AI's Expanding Role in Healthcare and Implications for Radiology
A series of thought leaders and institutions weigh in on AI's transformative potential in healthcare, with emphasis on radiology adoption and responsible use.
•Radiology Business
Most Radiology AI Users Lack Clear Evidence of Financial ROI
Survey finds over 75% of radiology organizations using AI lack clear, quantified ROI data.
•AuntMinnie
Toronto Study: LLMs Must Cite Sources for Radiology Decision Support
University of Toronto researchers found that large language models (LLMs) such as DeepSeek V3 and GPT-4o offer promising support for radiology decision-making in pancreatic cancer when their recommendations cite guideline sources.